37 related articles for article (PubMed ID: 11303619)
1. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
[TBL] [Abstract][Full Text] [Related]
2. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N; Kogan Y; Vainstein V; Agur Z
Cancer Immunol Immunother; 2008 Mar; 57(3):425-39. PubMed ID: 17823798
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.
Muldoon LL; Wu YJ; Pagel MA; Neuwelt EA
J Neurooncol; 2015 Feb; 121(3):433-40. PubMed ID: 25411097
[TBL] [Abstract][Full Text] [Related]
4. Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.
Flores C; Wildes T; Dean BD; Moore G; Drake J; Abraham R; Gil J; Yegorov O; Yang C; Dean J; Moneypenny C; Shin D; Pham C; Krauser J; King J; Grant G; Driscoll T; Kurtzberg J; McLendon R; Gururangan S; Mitchell D
Sci Adv; 2019 Nov; 5(11):eaav9879. PubMed ID: 31807694
[TBL] [Abstract][Full Text] [Related]
5. Attaining precision therapy in prostate cancer: A tall order.
Efstathiou E
Eur J Cancer; 2017 Aug; 81():226-227. PubMed ID: 28629596
[No Abstract] [Full Text] [Related]
6. Vascular Immune Evasion of Mesenchymal Glioblastoma Is Mediated by Interaction and Regulation of VE-Cadherin on PD-L1.
Luo J; Wang Z; Zhang X; Yu H; Chen H; Song K; Zhang Y; Schwartz LM; Chen H; Liu Y; Shao R
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686533
[TBL] [Abstract][Full Text] [Related]
7. A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.
Pinkiewicz M; Pinkiewicz M; Walecki J; Zawadzki M
Front Oncol; 2022; 12():950167. PubMed ID: 36212394
[TBL] [Abstract][Full Text] [Related]
8. PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes.
Menasche BL; Davis EM; Wang S; Ouyang Y; Li S; Yu H; Shen J
Sci Adv; 2020 Nov; 6(48):. PubMed ID: 33246952
[TBL] [Abstract][Full Text] [Related]
9. Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: a Systematic Review.
Huang R; Boltze J; Li S
Front Oncol; 2020; 10():1443. PubMed ID: 32983974
[TBL] [Abstract][Full Text] [Related]
10. Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity.
Marchi N; Teng Q; Nguyen MT; Franic L; Desai NK; Masaryk T; Rasmussen P; Trasciatti S; Janigro D
BMC Neurosci; 2010 Mar; 11():34. PubMed ID: 20214812
[TBL] [Abstract][Full Text] [Related]
11. Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.
Dasgupta A; McCarty D; Spencer HT
Biochem Biophys Res Commun; 2010 Jan; 391(1):170-5. PubMed ID: 19903457
[TBL] [Abstract][Full Text] [Related]
12. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.
Gomez GG; Read SB; Gerschenson LE; Santoli D; Zweifach A; Kruse CA
Neuro Oncol; 2004 Apr; 6(2):83-95. PubMed ID: 15134622
[TBL] [Abstract][Full Text] [Related]
13. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
15. Calbindin-D28k in subsets of medulloblastomas and in the human medulloblastoma cell line D283 Med.
Katsetos CD; Herman MM; Krishna L; Vender JR; Vinores SA; Agamanolis DP; Schiffer D; Burger PC; Urich H
Arch Pathol Lab Med; 1995 Aug; 119(8):734-43. PubMed ID: 7646332
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials with immunotherapy for high-grade glioma.
Ruzevick J; Jackson C; Phallen J; Lim M
Neurosurg Clin N Am; 2012 Jul; 23(3):459-70. PubMed ID: 22748658
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
